These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

346 related articles for article (PubMed ID: 19410314)

  • 21. Possibility of chest wall dose reduction using volumetric-modulated arc therapy (VMAT) in radiation-induced rib fracture cases: comparison with stereotactic body radiation therapy (SBRT).
    Murakami Y; Nakano M; Yoshida M; Hirashima H; Nakamura F; Fukunaga J; Hirose TA; Yoshioka Y; Oguchi M; Hirata H
    J Radiat Res; 2018 May; 59(3):327-332. PubMed ID: 29800456
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lung density changes after stereotactic radiotherapy: a quantitative analysis in 50 patients.
    Palma DA; van Sörnsen de Koste J; Verbakel WF; Vincent A; Senan S
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):974-8. PubMed ID: 20932655
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Predictors of Chest Wall Toxicity after Lung Stereotactic Ablative Radiotherapy.
    Thibault I; Chiang A; Erler D; Yeung L; Poon I; Kim A; Keller B; Lochray F; Jain S; Soliman H; Cheung P
    Clin Oncol (R Coll Radiol); 2016 Jan; 28(1):28-35. PubMed ID: 26129745
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lack of a dose-effect relationship for pulmonary function changes after stereotactic body radiation therapy for early-stage non-small cell lung cancer.
    Guckenberger M; Klement RJ; Kestin LL; Hope AJ; Belderbos J; Werner-Wasik M; Yan D; Sonke JJ; Bissonnette JP; Xiao Y; Grills IS
    Int J Radiat Oncol Biol Phys; 2013 Mar; 85(4):1074-81. PubMed ID: 23154077
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Applicability of the linear-quadratic formalism for modeling local tumor control probability in high dose per fraction stereotactic body radiotherapy for early stage non-small cell lung cancer.
    Guckenberger M; Klement RJ; Allgäuer M; Appold S; Dieckmann K; Ernst I; Ganswindt U; Holy R; Nestle U; Nevinny-Stickel M; Semrau S; Sterzing F; Wittig A; Andratschke N; Flentje M
    Radiother Oncol; 2013 Oct; 109(1):13-20. PubMed ID: 24183066
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Characterization of Chest Wall Toxicity During Long-term Follow Up After Thoracic Stereotactic Body Radiation Therapy.
    Chipko C; Ojwang J; Gharai LR; Deng X; Mukhopadhyay N; Weiss E
    Pract Radiat Oncol; 2019 May; 9(3):e338-e346. PubMed ID: 30731275
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Late chest wall toxicity after MammoSite breast brachytherapy.
    Brashears JH; Dragun AE; Jenrette JM
    Brachytherapy; 2009; 8(1):19-25. PubMed ID: 18955019
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dose-volume parameters predict for the development of chest wall pain after stereotactic body radiation for lung cancer.
    Mutter RW; Liu F; Abreu A; Yorke E; Jackson A; Rosenzweig KE
    Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):1783-90. PubMed ID: 21868173
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Stereotactic hypofractionated radiotherapy in stage I (T1-2 N0 M0) non-small-cell lung cancer (NSCLC).
    Zimmermann FB; Geinitz H; Schill S; Thamm R; Nieder C; Schratzenstaller U; Molls M
    Acta Oncol; 2006; 45(7):796-801. PubMed ID: 16982542
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Promising clinical outcome of stereotactic body radiation therapy for patients with inoperable Stage I/II non-small-cell lung cancer.
    Xia T; Li H; Sun Q; Wang Y; Fan N; Yu Y; Li P; Chang JY
    Int J Radiat Oncol Biol Phys; 2006 Sep; 66(1):117-25. PubMed ID: 16765528
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Stereotactic body radiation therapy can be used safely to boost residual disease in locally advanced non-small cell lung cancer: a prospective study.
    Feddock J; Arnold SM; Shelton BJ; Sinha P; Conrad G; Chen L; Rinehart J; McGarry RC
    Int J Radiat Oncol Biol Phys; 2013 Apr; 85(5):1325-31. PubMed ID: 23265574
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tolerance of organs at risk in small-volume, hypofractionated, image-guided radiotherapy for primary and metastatic lung cancers.
    Onimaru R; Shirato H; Shimizu S; Kitamura K; Xu B; Fukumoto S; Chang TC; Fujita K; Oita M; Miyasaka K; Nishimura M; Dosaka-Akita H
    Int J Radiat Oncol Biol Phys; 2003 May; 56(1):126-35. PubMed ID: 12694831
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fractionated stereotactic body radiation therapy for medically inoperable stage I lung cancer adjacent to central large bronchus.
    Song SY; Choi W; Shin SS; Lee SW; Ahn SD; Kim JH; Je HU; Park CI; Lee JS; Choi EK
    Lung Cancer; 2009 Oct; 66(1):89-93. PubMed ID: 19168260
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Stereotactic body radiation therapy for early-stage non-small-cell lung cancer: the pattern of failure is distant.
    Bradley JD; El Naqa I; Drzymala RE; Trovo M; Jones G; Denning MD
    Int J Radiat Oncol Biol Phys; 2010 Jul; 77(4):1146-50. PubMed ID: 19800181
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [An analysis of 20 consecutive patients treated with stereotactic body radiotherapy on Novalis Tx(®) for stage I non-small-cell lung cancer].
    Guillerme F; Clavier JB; Schumacher C; Falcoz PE; Bourrhala K; Santelmo N; Hassler S; Schott R; Quoix E; Massard G; Noël G
    Cancer Radiother; 2013; 17(4):272-81. PubMed ID: 23712043
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rib fracture after stereotactic radiotherapy for primary lung cancer: prevalence, degree of clinical symptoms, and risk factors.
    Nambu A; Onishi H; Aoki S; Tominaga L; Kuriyama K; Araya M; Saito R; Maehata Y; Komiyama T; Marino K; Koshiishi T; Sawada E; Araki T
    BMC Cancer; 2013 Feb; 13():68. PubMed ID: 23391264
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Stereotactic, high single-dose irradiation of stage I non-small cell lung cancer (NSCLC) using four-dimensional CT scans for treatment planning.
    Fritz P; Kraus HJ; Blaschke T; Mühlnickel W; Strauch K; Engel-Riedel W; Chemaissani A; Stoelben E
    Lung Cancer; 2008 May; 60(2):193-9. PubMed ID: 18045732
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of Tumor Location and Dosimetric Predictors for Chest Wall Toxicity in Single-Fraction Stereotactic Body Radiation Therapy for Stage I Non-Small Cell Lung Cancer.
    Manyam BV; Videtic GMM; Verdecchia K; Reddy CA; Woody NM; Stephans KL
    Pract Radiat Oncol; 2019 Mar; 9(2):e187-e195. PubMed ID: 30529796
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CyberKnife radiosurgery for stage I lung cancer: results at 36 months.
    Brown WT; Wu X; Fayad F; Fowler JF; Amendola BE; García S; Han H; de la Zerda A; Bossart E; Huang Z; Schwade JG
    Clin Lung Cancer; 2007 Sep; 8(8):488-92. PubMed ID: 17922973
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dosimetric predictors of radiation-induced lung injury in stereotactic body radiation therapy.
    Ricardi U; Filippi AR; Guarneri A; Giglioli FR; Mantovani C; Fiandra C; Anglesio S; Ragona R
    Acta Oncol; 2009; 48(4):571-7. PubMed ID: 19031164
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.